Show simple item record

dc.contributor.authorXu, Feng
dc.contributor.authorZhou, Huifen
dc.contributor.authorWu, Man
dc.contributor.authorZhang, Hong
dc.contributor.authorZhang, Yixian
dc.contributor.authorZhao, Qingbin
dc.contributor.authorBrown, Robert
dc.contributor.authorGong, Da-Wei
dc.contributor.authorMiao, Lining
dc.date.accessioned2020-09-10T18:22:09Z
dc.date.available2020-09-10T18:22:09Z
dc.date.issued2020-09-30
dc.identifier.urihttp://hdl.handle.net/10713/13674
dc.description.abstractEndotoxemia-induced acute kidney injury (AKI) is a common clinical condition that lacks effective treatments. Elabela (ELA) is a recently discovered kidney peptide hormone, encoded by the gene apela, and has been reported to improve cardio-renal outcomes in sepsis. However, ELA is a small peptide and is largely unsuitable for clinical use because of its short in vivo half-life. In the present study, we evaluated the potential renoprotective effects of a long-acting constant fragment (Fc)-ELA fusion protein in liposaccharide (LPS)-induced AKI in mice. LPS administration in mice for 5 days greatly lowered the gene expression of apela and impaired kidney function, as evidenced by elevated serum creatinine and the ratio of urine protein to creatinine. In addition, renal inflammation and macrophage infiltration were apparent in LPS-challenged mice. Treatment with the Fc-ELA fusion protein partially restored apela expression and attenuated the kidney inflammation. Moreover, LPS treatment induced reactive oxygen species (ROS) production and apoptosis in kidney HK-2 cells as well as in the mouse kidney, which were mitigated by ELA or Fc-ELA treatment. Finally, we found that ELA promoted the survival of HK-2 cells treated with LPS, and this action was abolished by LY204002, a PI3K/Akt inhibitor. Collectively, we have demonstrated that the Fc-ELA fusion protein has significant renoprotective activities against LPS-induced AKI in mice.en_US
dc.description.urihttps://doi.org/10.1042/BSR20192397en_US
dc.language.isoenen_US
dc.publisherSpringer Natureen_US
dc.relation.ispartofBioscience Reportsen_US
dc.rights© 2020 The Author(s).en_US
dc.subjectElabela (ELA)en_US
dc.subjectacute kidney injury (AKI)en_US
dc.subjectfusion proteinen_US
dc.subjectliposaccharide (LPS)en_US
dc.titleFc-Elabela fusion protein attenuates lipopolysaccharide-induced kidney injury in miceen_US
dc.typeArticleen_US
dc.identifier.doi10.1042/BSR20192397
dc.identifier.pmid32808659
dc.source.volume40
dc.source.issue9
dc.source.countryEngland


This item appears in the following Collection(s)

Show simple item record